The first participant has been dosed in a large clinical trial testing the experimental oral therapy votoplam (formerly PTC518) in adults with early-stage Huntington’s disease. That’s according to a press release from PTC Therapeutics, the therapy’s original developer, announcing its latest financial results and business updates.